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Abstract
Background: The C-terminal four amino acids (GEEV) of human 1A-adrenergic receptors (ARs)
have been reported to interact with the PDZ domain of neuronal nitric oxide synthase (nNOS) in
a yeast two-hybrid system. The other two 1-AR subtypes have no sequence homology in this
region, raising the possibility of subtype-specific protein-protein interactions.
Results: We used co-immunoprecipitation and functional approaches with epitope-tagged 1-ARs
to examine this interaction and the importance of the C-terminal tail. Following co-transfection of
HEK-293 cells with hexahistidine/Flag (HF)-tagged 1A-ARs and nNOS, membranes were
solubilized and immunoprecipitated with anti-FLAG affinity resin or anti-nNOS antibodies.
Immunoprecipitation of HF1A-ARs resulted in co-immunoprecipitation of nNOS and vice versa,
confirming that these proteins interact. However, nNOS also co-immunoprecipitated with HF1B-
and HF1D-ARs, suggesting that the interaction is not specific to the 1A subtype. In addition,
nNOS co-immunoprecipitated with each of the three HF1-AR subtypes which had been C-
terminally truncated, suggesting that this interaction does not require the C-tails; and with Flag-
tagged 1- and 2-ARs. Treatment of PC12 cells expressing HF1A-ARs with an inhibitor of nitric
oxide formation did not alter norepinephrine-mediated activation of mitogen activated protein
kinases, suggesting nNOS is not involved in this response.
Conclusions: These results show that nNOS does interact with full-length 1A-ARs, but that this
interaction is not subtype-specific and does not require the C-terminal tail, raising questions about
its functional significance.
Background
1-Adrenergic receptors (ARs) are G protein-coupled re-
ceptors that mediate some of the actions of norepine-
phrine and epinephrine. Three human 1-AR subtypes
have been cloned and named 1A, 1B and 1D-ARs[1].
These receptors regulate several important central and pe-
ripheral processes, such as neuronal excitability, vascular
and nonvascular smooth muscle contraction, and cellular
growth and differentiation. The three 1-AR subtypes are
structurally and pharmacologically distinct, but all couple
through Gq/11 to cause activation of apparently similar in-
tracellular signaling pathways.
The last four amino acids of the intracellular C-tail of the
1A-AR, GEEV, matches the motif G(D/E)XV shown previ-
ously to interact with the class III PDZ domain of neuron-
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al nitric oxide synthase (nNOS). Experiments using the
yeast two-hybrid system showed previously that a protein
corresponding to the last 114 amino acids of the rat 1A-
AR (previously referred to as 1C-AR) interacted strongly
with the PDZ domain of nNOS[2]. Since the correspond-
ing amino acids at the C-terminus of 1B (PGQF) and
1D-ARs (ETDI) would not be predicted to interact with
this PDZ domain, an interaction between 1A-ARs and
nNOS could represent an interaction unique to this sub-
type.
PDZ domains are protein-binding modules involved in
assembly of signaling complexes and subcellular protein
targeting[3]. For example, NMDA receptors in cultured
cortical neurons associate with nNOS through PSD-95, a
protein containing three PDZ domains[4]. Consequently,
NMDA receptor activation increases nitric oxide produc-
tion and neurotoxicity; while suppression of PSD-95 ex-
pression inhibits these responses. These results suggest
that the PDZ domains of PSD-95 may facilitate the assem-
bly of signaling complexes involving both NMDA recep-
tors and nNOS, and the increases in intracellular Ca2+
caused by NMDA receptor activation may facilitate nNOS
activation.
Since 1A-AR activation also increases intracellular Ca2+,
we studied the interaction between this receptor and
nNOS. We wanted to determine whether full-length 1A-
ARs interact with full-length nNOS, whether the interac-
tion is subtype-specific, and whether it involves the GEEV
motif in the C-terminal tail. We co-expressed epitope-
tagged full length or C-terminally truncated 1-ARs with
nNOS in HEK-293 cells and examined the ability of anti-
Flag and anti-nNOS antibodies to immunoprecipitate
both proteins. We found that nNOS does interact with
full-length 1A-ARs, but that it also interacts with other
1-AR subtypes and -ARs. In addition, the interaction
does not require the C-terminal tail, confirming that it is
not specific to the GEEV motif.
Results
Co-immunoprecipitation of nNOS with HF1A-ARs
To study the interaction between 1A-ARs and nNOS,
HEK-293 cells were transfected with rat nNOS and select-
ed with geneticin (400 g/ml). Western blots using an
anti-nNOS antibody showed a strong immunoreactive
band of ~170 kDa corresponding to nNOS in stably trans-
fected cells as expected, but little or no signal in untrans-
fected cells (data not shown). Expression of nNOS was
similar to that observed with equal amounts of rat brain
membrane protein run in parallel, suggesting similar ex-
pression levels. HEK-293 cells stably transfected with
nNOS were co-transfected with the cDNA encoding
HF1A-ARs. Expression levels of transiently transfected
1-ARs in these cells ranged from 100–500 fmol/mg pro-
tein, also similar to levels observed in rat brain. Cells were
then solubilized, immunoprecipitated with anti-Flag M2
affinity resin, eluted, and blotted with anti-Flag (Fig. 1A)
or anti-nNOS antibodies (Fig. 1B). Western blots of anti-
Flag immunoprecipitates showed that HF1A-ARs migrat-
ed as monomers of ~50 kDa (Fig. 1), and also appeared as
dimers and trimers, as reported previously[5]. Immuno-
precipitation of HF1A-ARs with anti-Flag affinity resin re-
sulted in co-immunoprecipitation of nNOS, as revealed
by the 170 kDa band detected in immunoblots using anti-
nNOS antibody (Fig. 1B). Note that nNOS immunoreac-
tivity was not present in anti-Flag affinity resin immuno-
precipitates from solubilized HEK-293 cells not
transfected with HF1A-ARs (Fig. 1B), showing that co-
immunoprecipitation of nNOS requires presence of the
tagged receptor construct.
Co-immunoprecipitation of nNOS with HF1B- and 
HF1D-ARs
To determine whether the interaction between nNOS and
1A-ARs was subtype-specific, cells stably expressing
nNOS were co-transfected with HF1B or HF1D-ARs, sol-
ubilized, immunoprecipitated with anti-Flag affinity res-
in, eluted, and blotted with anti-Flag (Fig. 2A) or anti-
nNOS antibodies (Fig. 2B). Monomers of the HF1B and
Figure 1
Immunoprecipitation with anti-Flag M2 affinity resin of solubi-
lized HEK-293 cells co-expressing nNOS and HF-tagged 1A-
AR (Flag-A/nNOS) or HEK-293 expressing only nNOS (HEK/
nNOS). Cells were solubilized, immunoprecipitated with
anti-Flag M2 affinity resin, eluted with Flag peptide, run on
SDS-PAGE, and transferred to nitrocellulose as described in
Methods. A: Western blot with M2 anti-Flag antibody with
arrows showing monomers, dimers and trimers; B: Western
blot with anti-nNOS antibody. Blots are representative of at
least two other experiments with similar results. IP = immu-
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HF1D-ARs migrated as bands of ~65 and ~75 kDa (Fig.
2A), and dimers and trimers were also detected. Surpris-
ingly, nNOS was also co-immunoprecipitated from cells
co-expressing nNOS and HF1B or HF1D-ARs (Fig. 2B),
although the GEEV motif predicted to interact with nNOS
is not present in either of these subtypes.
Interaction of C-terminally truncated HF1-ARs with 
nNOS
The role of the C-terminus of 1-ARs in the interaction
with nNOS was examined by truncation. Stop codons
were introduced approximately 20 amino acids after the
predicted 7th transmembrane domain, at a conserved
glutamine (1A, Gln 344; 1B, Gln 366) or an adjacent ar-
ginine (1D, Arg 418). Truncated HF1-ARs were trans-
fected into HEK-293 cells stably expressing nNOS, and
cells were solubilized, immunoprecipitated with anti-Flag
M2 affinity resin, and blotted with anti-Flag (Fig. 3A) or
anti-nNOS antibodies (Fig. 3B). The monomeric truncat-
ed receptors migrated with molecular masses ~25% lower
than that of the full length receptors (Fig. 3A), and higher
order oligomers were also apparent as observed with full-
length receptors. Specific immunoreactivity to anti-nNOS
antibody was also detected in these immunoprecipitates
(Fig. 3B), showing that the C-terminal cytoplasmic tail of
the HF1-ARs is not required for interaction.
Co-immunoprecipitation of HF-tagged 1-ARs with anti-
nNOS antibody
We also examined the ability of anti-nNOS antibodies to
co-immunoprecipitate full length and truncated HF1-
ARs. HEK-293 cells expressing nNOS were transfected
with each receptor construct and harvested after 48–72 hr.
Samples were solubilized, incubated with anti-nNOS an-
tibody, immunoprecipitated with Protein A agarose, and
blotted with anti-Flag antibody. This procedure resulted
in a strong non-specific band migrating at ~50 kDa (ap-
proximately the size of the HF1A-AR), probably repre-
senting IgG heavy chains. For comparison, parallel
samples were immunoprecitated with anti-Flag affinity
resin and loaded on the same gel. Fig. 4A shows that anti-
nNOS antibodies caused co-immunoprecipitation of all
three full length and truncated HF1-ARs. Note that nei-
ther protein A agarose alone, nor anti-nNOS antibody
plus Protein A agarose, caused immunoprecipitation of
HF1-ARs in cells not expressing nNOS (data not shown).
This indicates that HF1-ARs do not nonspecifically inter-
act with anti-nNOS antibody and/or protein A agarose.
Co-immunoprecipitation of nNOS with Flag-tagged 1- 
and 2-ARs
To further examine the specificity of this interaction, HEK-
293 cells stably expressing nNOS were co-transfected with
Flag-tagged 1 or 2-ARs, solubilized, immunoprecipitat-
Figure 2
Immunoprecipitation with anti-Flag M2 affinity resin of solubi-
lized HEK-293 cells co-expressing nNOS and HF-tagged 1B-
(Flag-B/nNOS) or 1D-ARs (Flag-D/nNOS) or HEK-293 cells
expressing only the HF-tagged 1-AR subtypes (Flag-B, Flag-
D). A: Western blot with anti-Flag antibody; arrows indicate
monomers, dimers and trimers of the HF-tagged 1B-
(closed) and 1D- (open) ARs. B: Western blot with anti-
nNOS antibody. Blots shown are representative of at least
two other experiments with similar results. IP = immunopre-


















Immunoprecipitation with anti-Flag M2 affinity resin of solubi-
lized HEK-293 cells expressing C-terminally truncated HF-
tagged 1-AR subtypes (Flag-trA, Flag-trB and Flag-trD) and
nNOS. A: Western blot with anti-Flag M2 antibody; arrows
indicate positions of monomers and dimers. B: Western blot
with anti-nNOS antibody; arrow indicates nNOS. Blots
shown are representative of at least two other experiments
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ed with anti-Flag affinity resin or anti-nNOS antibody
plus Protein A agarose, and blotted with anti-Flag (Fig.
5A) or anti-nNOS antibodies (Fig. 5B). Fig. 5A shows that
both Flag-tagged 1 and 2-ARs migrated as monomers
(1 at ~70 kDa and 2 at ~50 kDa) as well as oligomers
(data not shown), and that immunoprecipitation of
nNOS caused co-immunoprecipitation of both Flag-
tagged 1 or 2-ARs. Fig. 5B shows that nNOS was also ob-
served following immunoprecipitation with anti-Flag M2
affinity resin in cells transfected with either Flag-tagged 1
and 2-ARs.
Effect of l-NAME on 1A-AR-induced ERK activation in 
PC12 cells
It is known that nitric oxide produced by nNOS is re-
quired for PC12 cell differentiation induced by nerve
growth factor (NGF) and that treatment of PC12 cells with
NGF induces nNOS expression[6]. Since 1A-AR stimula-
tion also activates ERKS and induces differentiation in
PC12 cells stably transfected with this subtype[7], we in-
vestigated the effects of l-NAME, an inhibitor of NOS, on
norepinephrine-induced ERK phosphorylation in PC12
cells stably transfected with HF1A-ARs. Fig. 6 shows that
treatment of HF1A-PC12 cells with high concentrations
of l-NAME did not block ERK phosphorylation induced
by norepinephrine, or by UTP, EGF or NGF, suggesting
Figure 4
Immunoprecipitation with anti-nNOS antibody of solubilized HEK-293 cells co-expressing nNOS and HF-tagged full length
(Flag-A, Flag-B, Flag-D) or C-terminally truncated (Flag-trA, Flag-trB, FlagtrD) 1-AR subtypes. For comparison, immunoprecip-
itation of HF-tagged receptors with anti-Flag M2 affinity resin is also shown. Monomers of each full-length and truncated sub-
type are indicated by arrows on the left of each blot. Blots shown are representative of at least two other experiments with


























Immunoprecipitation with anti-nNOS antibody or anti-Flag
M2 affinity resin of solubilized HEK-293 cells co-expressing
nNOS and Flag-tagged 1- or 2-ARs. A: Western blot with
anti-Flag antibody; B: Western blot with anti-nNOS antibody.
Blots shown are representative of at least two other experi-
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that nitric oxide is not required for mitogenic signals in
this cell line.
Discussion
We evaluated the specificity and functional importance of
the reported interaction of the C-terminus of 1A-ARs
with the PDZ domain of nNOS. Previous work using a
yeast two hybrid assay showed that the C-terminal 114
amino acids of rat 1A-ARs (referred to by the previous
name of 1C-) strongly interacted with residues 1–111 of
nNOS[2]. The bradykinin B2 receptor, also a G protein
coupled receptor, has been shown to bind directly to the
oxygenase domain of nNOS and form an inhibitory com-
plex[8], and it has been proposed that nNOS is released
and activated upon receptor stimulation. The domain of
the bradykinin B2 receptor that interacts with nNOS is in
the C-tail shortly after the predicted 7th transmembrane
domain, and spatially similar but structurally dissimilar
domains of the rat angiotensin AT1 receptor and human
endothelin-1 ETB receptors have been proposed to block
endothelial NOS (eNOS) activity, possibly through a sim-
ilar mechanism[9]. Therefore we wanted to determine
whether there was a specific interaction between full-
length 1A-ARs and nNOS in intact cells.
Co-immunoprecipitation experiments showed that
epitope-tagged 1A-ARs do interact with full-length nNOS
when expressed together in HEK-293 cells. Immunopre-
cipitation of HF1A-ARs from cells stably expressing
nNOS caused co-immunoprecipitation of nNOS. Similar-
ly, immunoprecipitation of nNOS caused co-immunopre-
cipitation of HF1A-ARs. This interaction appeared to be
specific, since nNOS was not immunoprecipitated by anti-
Flag affinity resin in cells not transfected with tagged re-
ceptors, and tagged receptors were not immunoprecipitat-
ed by anti-nNOS antibody in cells not expressing nNOS.
These results support an interaction between nNOS and
1A-ARs, which could be due to the previously reported
interaction of the receptor C-terminus and the PDZ do-
main of nNOS[2]. However, this hypothesis is weakened
by the unexpected observation that nNOS also co-immu-
noprecipitates with both 1B and 1D-ARs. There is little
or no homology between the C-terminal sequences of
1A, 1B and 1D-ARs, and neither 1B nor 1D-ARs con-
tain the GEEV motif predicted to mediate the interaction
between 1A-ARs and nNOS. However, nNOS was found
to co-immunoprecipitate with both HF1B- and HF1D-
ARs after co-expression in HEK-293 cells. These interac-
tions could be observed by blotting for the tagged recep-
tors after immunoprecipitation with anti-nNOS antibody,
or by blotting for nNOS after immunoprecipitation of the
tagged receptors with anti-Flag antibody. Direct compari-
son of 1A,  1B and 1D-ARs in the same experiment
showed similar degrees of interactions of all three sub-
types with nNOS (data not shown), further demonstrat-
ing that this interaction is not specific to the 1A subtype.
We examined the role of the C-terminal tail in this inter-
action by constructing receptors in which the C-terminus
was truncated. Studies with HF1-AR subtypes with short
(~20 aa) C-terminal tails suggested that the C-terminal
tails are not required for interaction with nNOS. Follow-
ing transfection into nNOS-expressing cells, immunopre-
cipitation of all three C-terminally truncated HF1-AR
constructs caused co-immunoprecipitation of nNOS sim-
ilar to that observed with full-length receptors. Although
PDZ domains of some proteins, such as PSD-95 and syn-
trophin, can bind internal peptide sequences that fold as
-fingers and mimic canonical C-terminal pep-
tides[10,11], there is very little homology between the in-
tracellular loops of 1-AR subtypes, making it unlikely
that there is a common internal amino acid sequence in-
volved in interaction with nNOS.
Since we found nNOS to co-immunoprecipitate with all
three  1-AR subtypes, we also determined whether it
would directly associate with -ARs. Flag-tagged 1 and
2-ARs were transfected into cells stably expressing nNOS,
and after solubilization and immunoprecipitation with
Figure 6
Effect of L-NAME (500 M) on UTP (100 M), norepine-
phrine (NE, 100 M), NGF (100 ng/ml) and EGF(100 ng/ml)
induced ERK phosphorylation in PC12 cells. HF1A-trans-
fected PC12 cells were serum-starved for 2 hr, pretreated
with L-NAME for 30 min, and exposed to agonist for 15 min
before harvesting. ERK activation was determined by West-
ern blotting with dual phospho-specific ERK antibodies as
described in Methods. Although the blot shown is overex-
posed, similar strength of signals were seen with NE, NGF
and EGF after shorter exposures.
basal
L-NAME -- + -+-+-+
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anti-Flag M2 affinity resin we again found co-immunopre-
cipitation of nNOS. Since 1 and 2-ARs show no se-
quence homology to 1-AR subtypes in their intracellular
domains, this further supports the conclusion that inter-
action with nNOS is not localized to discrete intracellular
domains.
Conclusions
Our data suggest that full-length 1A-ARs do interact with
nNOS; however this interaction is not subtype-specific
since 1B- and 1D-ARs showed similar interactions. The
interaction did not require the receptor C-terminus, and
similar interactions were observed with 1 and 2-ARs.
This data does not support a proposed specific interaction
between the 1A-AR C-terminus and the nNOS PDZ do-
main suggested by studies with fusion proteins. Studies
on 1A-ARs in transfected PC12 cells showed no role for
nitric oxide in mitogenic signaling, also raising questions
about the functional significance of this interaction.
Methods
Materials
HEK-293 cells were purchased from ATCC. PC12 cells
were obtained from Cindy Miranti and Michael Green-
berg (Harvard Medical School, Boston, MA, USA). The
cDNA encoding rat nNOS was from Dr. Thomas Michel
(Harvard Medical School, Boston, MA), the human 1A-
AR cDNA [12] from Dr. Gozoh Tsujimoto (National Chil-
dren's Hospital, Tokyo, Japan), the human 1B-AR cD-
NA[13] from Dr. Dianne Perez (Cleveland Clinic), and
the human 1D-AR cDNA[14] was cloned in our lab. Ma-
terials were obtained from the following sources: Dulbec-
co's modified Eagle's medium (DMEM); L-NAME;
norepinephrine ((-)-arterenol); streptomycin, penicillin,
Flag peptide, anti-Flag M2 affinity resin, HRP-conjugated
anti-Flag M2 antibody and goat anti-rabbit HRP-conjugat-
ed secondary antibodies (Sigma, St Louis, MO); geneticin;
n-Dodecyl--D-maltoside (Calbiochem); anti-nNOS rab-
bit polyclonal antibody, Protein A-agarose resin (Santa
Cruz); rabbit polyclonal dual phospho-specific anti-ERK
antibody, PNGase F (New England Biolabs); and ECL re-
agent (Amersham).
Cell culture
HEK-293 cells were propagated in Dulbecco's Minimal Es-
sential Medium with sodium pyruvate, 10% heat inacti-
vated fetal bovine serum, 100 U/l streptomycin, and 100
U/l penicillin at 37C in a humidified atmosphere with
5% CO2. Confluent plates were subcultured at a 1:3 ratio.
PC12 cells were propagated in Dulbecco's Minimal Essen-
tial Medium containing 4.5 g/l glucose, 1.4% glutamine,
20 mM Hepes, 100 U/l streptomycin, 100 U/l penicillin,
10% donor horse serum, and 5% fetal bovine serum. For
measurement of ERK phosphorylation, 35 mm dishes of
PC12 cells were seeded at a density of 600,000 cells/2 ml.
Transfections
Receptor coding sequences were generated by PCR, se-
quenced, and subcloned into the mammalian expression
plasmid pDT containing sequential N-terminal hexahisti-
dine and FLAG (HF) epitopes as previously described[5].
HEK-293 cells (150 mm plates) were transfected with 50
g cDNA encoding the rat isoform of nNOS by calcium
phosphate precipitation, and stably transfected cells se-
lected with geneticin (400 g/ml). cDNAs encoding each
of the HF-human 1-ARs were transfected into parental
HEK-293 cells or cells stably transfected with nNOS by
calcium phosphate precipitation and cells harvested 48–
72 h later. The density of HF1-ARs was measured by spe-
cific binding of [125I]-HEAT[7], and ranged from 100–
500 fmol/mg protein.
Immunoprecipitation
HEK-293 cells expressing HF-tagged 1-ARs, nNOS, or
both, were harvested by scraping and fractionated by re-
peated centrifugation and homogenization. Cell lysates
(1–2 mg protein) were solubilized in 1X buffer (25 mM
Hepes and 150 mM NaCl, pH 7.4) with 2% n-Dodecyl--
D-maltoside for 90 min at 4C in buffer A (25 mM HEPES,
150 mM NaCl, pH 7.4) supplemented with protease in-
hibitors (aprotinin 2 g/ml, leupeptin 2 g/ml, pepstatin
2 g/ml, benzamidine 2 g/ml, PMSF 2 mM, and EDTA
50 mM). Solubilized samples were centrifuged, the super-
natant diluted 10-fold with buffer A containing protease
inhibitors, and incubated with 100–200 l anti-Flag M2
affinity resin for 90 min at 4C with gentle rotation[5]. Al-
ternatively, the supernatant was incubated with 5 l of
anti-nNOS rabbit polyclonal antibody (200 g/ml) for 90
min at 4C and then incubated with 20 l Protein A-agar-
ose overnight at 4C. Immunoprecipitated material was
recovered by centrifugation and washed at least 4 times
with buffer A containing protease inhibitors. After wash-
ing, samples immunoprecipitated with anti-Flag affinity
resin were eluted with 100 to 200 l buffer A containing
400 g/ml Flag peptide, while samples immunoprecipi-
tated with anti-nNOS antibody were eluted with 40l of
2X Laemmli loading buffer. All samples were deglyco-
sylated after immunoprecipitation by treatment with 1 l
PNGase F for 2 h at room temperature. Aliquots of 30 l
were separated by 4–20% SDS-PAGE, transferred to nitro-
cellulose, and blotted with anti-Flag M2 antibodies conju-
gated to HRP (1:600) or anti-nNOS rabbit polyclonal
antibodies (1:1,000) followed by goat anti-rabbit HRP-
conjugated secondary antibodies (1:15,000). Proteins
were visualized by ECL.
ERK phosphorylation in PC12 cells
Confluent PC12 cells stably transfected with HF-1A-
ARs[15] (~1 pmol/mg of protein) were serum-starved for
2 h before use, and incubated with or without l-NAME
(500 M/30 min). Cells were then incubated with nore-BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/17
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pinephrine or other agonists for 15 min and lysed with
Laemmli sample buffer. Cell lysates were centrifuged and
proteins (10 g/lane) were separated by SDS-PAGE and
transferred to nitrocellulose membranes. Phosphoryla-
tion of ERKs was detected by immunoblotting using a
1:1000 dilution of rabbit polyclonal dual phospho-specif-
ic ERK antibodies with HRP-conjugated goat anti-rabbit
IgG as a secondary antibody and visualized by ECL.
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